Microbiome modulator

0 marketed 2 in Phase 3

This page covers all Microbiome modulator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Alginate lyase.

Targets

Phase 3 pipeline (2)

RP-G28 · Ritter Pharmaceuticals, Inc. · Gastroenterology / Metabolic Disease
RP-G28 is a non-systemic oral therapeutic that modulates the gut microbiome to improve metabolic and immune function.
ALGRX 3268 · AlgoRx Pharmaceuticals · Gastroenterology / Immunology
ALGRX 3268 is a selective inhibitor of alginate lyase that modulates the gut microbiome by targeting bacterial polysaccharide degradation.